Skip to content
Issue Areas
Events
Publications
Connect With Us
About Us
2022 Snapshot
About IHP
Meet the Team
Contributing Authors
Search
Menu
Search
Submit
Drug Policy
A deeper dive: Recommendations for strengthening the FDA’s REMS program to protect patients
Our thoughts on HHS’s blueprint to lower drug prices: It’s time for a new legal and policy landscape
Reflections on high drug pricing in America: Where we are and where we’re headed
A provider and payor’s perspective on drug pricing
What the US can learn about drug pricing from Australia, the U.K. and Germany
Sovaldi, Harvoni, and why it’s different this time
Back To Top
Search
Submit